

CLINICAL STUDY PROTOCOL PRINCIPAL INVESTIGATOR AGREEMENT FORM

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

D702NC00001	VERSION 1.0 AND DATE 08 Aug 2025
-------------	----------------------------------

I agree to the terms of this version of the Clinical Study Protocol and will conduct the study according to the procedures specified herein (and any other referenced documents), and according to the principles of Good Clinical Practice (GCP) and local regulations. I will ensure that all associates, colleagues and employees assisting in the conduct of the study are informed of their obligations and will be kept informed throughout the study.

I understand that the protocol may not be modified without written approval of the sponsor.

All versions of the protocol must be submitted to the applicable regulatory authority and Institutional Review Board (IRB)/Independent Ethics Committee (IEC), and must be approved by the IRB/IEC prior to implementation except when necessary to eliminate immediate hazards to patients or when changes are of an administrative nature. Documentation of IRB/IEC approval must be sent to the sponsor immediately upon receipt.

Role in the study:	Principal Investigator
Name and title:	Dr. Prashant Pandey Consultant Of Medical Oncology
Address including postal code:	Tata Medical Center 14 MAR(E-W), Newtown, Rajarhat, Kolkata-700160
Telephone number:	+91-9804290687
Site/Centre Number (if available):	3514
Signature:	<i>Prashant Pandey</i>
Date of signature:	21/08/2026

This document contains confidential information, which should not be copied, referred to, released, or published without written approval from AstraZeneca. Investigators are cautioned that the information in the protocol may be subject to change and revision.